Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28149986 | 0.86 | HDAC1 (0.40) | HDAC1HDAC6DYRK1A | |
| SCHEMBL17658980 | 0.84 | NUDT1 (0.40) | HDAC1HDAC6DYRK1A | |
| SCHEMBL20260744 | 0.80 | CFTR (0.37) | CFTR | |
| SCHEMBL22943013 | 0.77 | ALDH1A1 (0.32) | CFTR | |
| SCHEMBL20759271 | 0.74 | DYRK1A (0.37) | HDAC1HDAC6DYRK1A | |
| SCHEMBL21468722 | 0.74 | DYRK1A (0.37) | HDAC1HDAC6DYRK1A | |
| SCHEMBL23364840 | 0.74 | CFTR (0.35) | CFTR | |
| SCHEMBL20239860 | 0.74 | L3MBTL1 (0.35) | CFTR | |
| SCHEMBL21468591 | 0.74 | — | — | |
| SCHEMBL22943016 | 0.73 | DYRK1A (0.33) | HDAC1HDAC6DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220257564-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-08-18 | — | — | US | disclosed |
| US-20210139514-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2021-05-13 | — | — | US | disclosed |
| US-20210032272-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032272-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | CFTR, SCNN1G, CLCN2 | HDAC1 3523/4885HDAC6 1286/4885DYRK1A 4665/4885 |
| US-20210139514-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | HDAC1 3207/4885HDAC6 1313/4885DYRK1A 4647/4885 |
| US-20220257564-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | CFTR, PKD1, ABCB11 | HDAC1 1820/4885HDAC6 502/4885DYRK1A 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.